I-MED Pharma Inc., a Canadian company specializing in dry eye diagnosis and management, announced today that the company has launched I-DEFENCE®, a long-lasting, lubricating dry eye ointment that delivers superior moisturizing and protection of the ocular surface.
A photo accompanying this announcement is available at LINK_TBD_by_Marketwire
The unique viscous properties of I-DEFENCE® enable a prolonged contact-time with the ocular surface. This hydrating ointment provides soothing relief of dry eye symptoms, such as soreness, irritation, or a gritty sensation on the eyes, while acting as a barrier against moisture loss. It is ideal for night-time use.
Ilan Hofmann, Chairman and Chief Scientific Officer of I-MED Pharma stated, “I-DEFENCE®’s formulation is extremely effective at providing maximum, long-lasting relief of dry eye symptoms, and is well tolerated by patients. We are pleased to expand our dry eye portfolio to include an ointment that will continuously lubricate and hydrate the eyes throughout the night. We recommend I-DEFENCE® for patients that suffer from severe chronic dry eyes and lagophthalmos symptoms. We are confident that I-DEFENCE® will be met with favorable results by both eye care professionals and their patients.”
I-MED Pharma is a privately held Canadian company, headquartered in Montreal, Quebec, servicing Canadian ophthalmologists, optometrists, and the international eye care community. Established more than thirty years ago, I-MED Pharma Inc. creates and distributes innovative medical, surgical, and veterinary eye care products. It continually researches, develops, and sources the most effective and advanced solutions to eye disorders like cataracts, corneal degenerations, glaucoma, dry eye, and meibomian gland disease.
I-MED Pharma is proud to have been at the forefront of managing Dry Eye Syndrome as a serious disease and invests heavily in researching and developing effective dry eye products. I-MED Pharma’s ocular surface disease product range includes dry eye drops, ocular hygiene cleansers, nutritional supplements, therapeutic accessories, and ocular occlusion devices.